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ABSTRACT 
Objective:  The aim of this study was to determine the preoperative predictors of the extent of resection and 
endocrinological remission following endonasal endoscopic removal of growth hormone (GH) – secreting 
pituitary adenomas. Trans-sphenoidal surgery is the preferred treatment modality for growth hormone (GH) – 
secreting pituitary adenomas. In many series, the reported postoperative remission is based mainly on achieve-
ment of GH levels less than 2 ng/ml. Strict criteria for insulin – like growth factor I normalization and even lower 
GH levels (< 1 ng/ml) are now suggested to define cure of acromegaly, but the evidence does not yet support such 
low GH levels in epidemiological follow-up. We analyzed our postoperative results in a sample of local popu-
lation with acromegaly. 
Methods:  Seven patients harboring GH – secreting adenomas (07 macroadenomas) underwent transsphenoidal 
surgery between 2005 and 2007 in Lahore General Hospital. The patient group included 03 women and 04 men 
of 23 – 50 years of age. All the patients were operated for the first time. Biochemical remission was defined as a 
repeated fasting or glucose – suppressed GH level of 2 ng/ml or less, and a normal insulin – like growth factor I 
level. 
Results:  The majority of acromegalic patients (83%) had macroadenomas > 1 cm in maximum diameter. Gross – 
total resection was achieved in 05 (71%) of 07 patients. Notably, endoscopic transsphenoidal surgery allowed 
complete resection of all lesions without cavernous sinus invasion, regardless of the suprasellar extent. 
Biochemical remission was achieved in 06 (85%) of 07 patients. A postoperative reduction in GH serum levels 
were associated with a higher rate of biochemical cure (p < 0.05). Significant differences were observed between 
pre- and postsurgical serum GH levels in male patients with Acromegalic tumors. Although mean serum GH 
concentrations were discernibly higher in patients as compared to controls (30.2 ± 3.1 vs 0.4 ± 0.1). In all the 
three premenopausal female patients included in the study, the individual presurgical serum GH levels were 
greater than those following surgery. The mean value was significantly higher than of the controls (38.9 ± 10.3 vs 
0.2 ± 0.6 ng/ml, respectively).These values exceeded the normal serum GH concentrations described for healthy 
women (7 ng/ml or less). Following surgical removal of the adenoma, serum GH concentrations showed a 
marked decline of GH levels in all patients. 
Conclusion:  A purely endoscopic endonasal trans-sphenoidal adenoma resection leads to a high rate of gross – 
total tumor resection and endocrinological remission in acromegalic patients, even those harboring macro-
adenomas with wide suprasellar extension. Extended approaches and angled endoscopes are useful tools for 
increasing the extent of resection. 
Key Words:  Growth hormone – secreting pituitary adenoma,Cavernous sinus, Remission induction. 
 
INTRODUCTION 
Acromegaly results from supraphysiological growth 
hormone (GH) release from pituitary somatotroph ade-
nomas (99% of cases), resulting in persistently high 
circulating levels of GH.
1
 The name acromegaly 
comes from the Greek words for ―extremities‖ and 
―enlargement,‖ reflecting one of its most common 
symptoms — the abnormal growth of the hands and 
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feet. Swelling of the hands and feet is often an early 
feature, with patients noticing a change in ring or shoe 
size, particularly shoe width. Gradually, bone changes 
alter the patient‘s facial features: The brow and lower 
jaw protrude, the nasal bone enlarges, and the teeth 
space out.
1,2
 
 Acromegaly is most often diagnosed in middle – 
aged adults, although symptoms can appear at any age. 
If not treated, acromegaly can result in serious illness 
and premature death.
2
 Acromegaly is treatable in most 
patients, but because of its slow and often ―sneaky‖ 
onset, it often is not diagnosed early or correctly. The 
most serious health consequences of acromegaly are 
type 2 diabetes, high blood pressure, increased risk of 
cardiovascular disease, and arthritis. Patients with 
acromegaly are also at increased risk for colon polyps, 
which may develop into colon cancer if not removed.
3
 
 It has an annual incidence of three to four cases 
per 1 million people and a prevalence of approxima-
tely 60 per million.
3
 Overall, there appears to be no 
difference in race, gender or ethnicity among indivi-
duals affected with this condition. Several retrospec-
tive cohort studies suggest that mortality in acrome-
galy is at least twice that in the general population.
2,5-8
 
The cardiovascular effects such as hypertension, car-
diomyopathy and valvular heart disease are associated 
with increased morbidity and premature mortality, and 
significant increases have been reported for both respi-
ratory disorders and malignancies.
8-10
 The most recent 
consensus guidelines for the management of acrome-
galy suggest surgery as the first – line therapy, either 
alone or in combination with medical treatment, con-
ventional radiotherapy and/or radiosurgery.
10-12
 But, 
the cavernous sinus invasion renders the tumor surgi-
cally unresectable even in skilled hands, and remains 
one of the greatest challenges in neurosurgery. The 
residual tumor within the cavernous sinus can continue 
to cause endocrinological symptoms, which necessita-
tes further treatment such as pharmacological therapy 
or radiotherapy. We analyzed the surgical results of 07 
patients with GH – secreting pituitary adenomas in a 
sample of local population. 
 
MATERIALS AND METHODS 
Study Population 
The present study initially included 7 patients 4 men 
and 3 women, of 23 – 50 years of age with FPAs. All 
patients underwent pituitary tumour surgery. The 
adenoma was removed in all patients through trans-
sphenoidal route. All cases were operated at the 
Department of Neurosurgery, Lahore General Hospi-
tal, Lahore between January 2005 and February 2007. 
 The study also included 7 sex and age matched 
healthy subjects that served as the control group with 
23 – 50 years of age. Subjects included in the control 
group had no medical history of any chronic disease 
and were not on current or past medication of steroids, 
antipsychotropic and other medications known to affe-
ct pituitary hormone secretion. The subjects fulfilling 
inclusion criteria were enrolled in the study after obtai-
ning his/her written informed consent. The study was 
approved by the Ethical Committee and the Advanced 
Studies and Research Board of the University of Heal-
th Sciences, Lahore. 
 
Sample Collection 
Blood samples from patients with pituitary adenomas 
were obtained prior to surgery and 2 months after 
removal of the pituitary adenoma. Following surgery, 
patients received 10 mg prednisolone daily for 6 
weeks. Postsurgical serum samples were obtained 2 
weeks after the prednisolone treatment was disconti-
nued. Blood samples were also obtained from an equal 
number of age and sex matched control subjects for 
purpose of comparison. Five ml of blood sample were 
drawn from each patient and blood was centrifuged at 
3,000 rpm for 10 – 15 minutes to separate serum and 
aliquoted in two portions and stored at -30ºC until ana-
lyzed. 
 The pituitary adenoma tissue was divided into two 
parts. One part was fixed in buffered formalin and pro-
cessed for histological examination, whereas the other 
half was weighed and homogenized in ice – cold phos-
phate buffer saline (PBS), at a dilution of approxi-
mately 50 mg/ml. The samples were centrifuged for 30 
min at 10000 rpm and the supernatant was frozen at 
-30
o
C. 
 
Tissue Biology 
Following fixation, adenoma tissue was processed for 
histopathological examinations. Paraffin sections of 
the tissue were cut at a thickness of 3 – 5 µm and stai-
ned routinely with hemotoxylin and counterstained 
with eosin. 
 
Hormone Determinations 
Serum GH was determined by ELISA in duplicate 
using standard procedures with commercially available 
assay GH: BioCheck, Inc, Foster City, CA, USA; 
PRL: Monobind Inc, Costa Mesa, CA, USA) with an 
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automated EIA analyzer (Coda, Bio-Rad Laboratories, 
Hercules, CA, USA). 
 
Statistical Analysis 
The significance of differences among different groups 
was analyzed by one way analysis of variance (ANO-
VA) followed by Duncan‘s multiple t-test. P value of 
< 0.05 was considered statistically significant. All cal-
culations were carried out with the SPSS version 12 
(SPSS Inc, Chicago, IL, USA). 
 
RESULTS 
Growth Hormone (GH) 
Males 
Significant differences were observed between pre- 
and postsurgical serum GH levels in male patients 
with Acromegalic tumors (Tables 1, 2 and Fig. 1) al-
though mean serum GH concentrations were slightly 
but discernibly higher in patients as compared to 
controls (30.2 ± 3.1 vs 0.4 ± 0.1). 
 
Females 
In all the three premenopausal female patients inclu-
ded in the study, the individual pre-surgical serum GH 
levels were greater than those following surgery 
(Table 3). The mean value was significantly higher 
than of the controls (38.9 ± 10.3 vs 0.2 ± 0.6 ng/ml, 
respectively). As shown in Table 3, 4 and Fig 2. These 
values exceeded the normal serum GH concentrations 
described for healthy women (7 ng/ml or less). Follo-
wing surgical removal of the adenoma, serum GH 
concentrations showed a marked decline of GH levels 
in all patients. 
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Figure 1: Mean ± SEM serum concentration of GH (ng/ 
ml) in 04male patients with FPA and age – mat-
ched control subjects. The values with different 
superscripts (a,b) are different from each other 
(P <0.05; ANOVA followed by Duncan‘s t-test). 
 
DISCUSSION 
In the present study, we have attempted to assess the 
hormonal contribution of the pituitary adenomas diag-
nosed as functioning, by measuring pituitary hormones 
in serum before and after surgical removal of the tum-
our. Preoperative data such as age and sex distribution, 
preoperative GH concentration were comparable with 
those from other studies.
1,3,14,21
 
 An endocrinological ―cure‖ for acromegaly, as 
defined by the stringent criteria of biochemical remis-
sion
10,21
 was achieved in 85% of patients, similar to 
that reported in the most recent series.
16,19-21,25
 TSS 
remains an effective treatment for acromegaly, whe-
reas medical treatment and / or radiotherapy should 
be reserved for patients with persistent GH / IGF – I
 
Table 1: Serum GH levels in male patients with Functioning Pituitary Adenomas and in age – matched control 
subjects. 
 
 HUMAN GROWTH HORMONE SERUM SAMPLES 
   Pre-surgical Post-surgical  
ID Sex Age Years 
wt. of Pituitary 
adenoma (mg) 
Pre GH 
(ng/ml) 
Post GH 
(ng/ml) 
Control GH 
(ng/ml) 
P.A 23 Male 40 124.1 31.3 1.4 0.5 
P.A 25 Male 42 114.2 22.2 3.5 0.2 
P.A 27 Male 35 8.4 7.5 8.6 0.4 
P.A 11 Male 32 19.2 19.8 4.3 0.9 
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Table 2: Mean ± SEM serum GH levels of male 
patients with Functioning Pituitary Adeno-
mas and in normal subjects. 
 
Group 
Serum GH 
(ng/ml) 
Males 
Control Subjects (n = 04) 
Patients with pituitary adenoma (n = 07) 
  0.4 ± 0.1 
Pre-surgical 30.2 ± 3.1 
Post-surgical   4.4 ± 1.5* 
 
*Significantly different from pre-surgical and control value 
(P < 0.05; ANOVA followed by Duncan‘s t- test). 
 
hypersecretion after surgery.
4
 
 However, for patients with cavernous sinus inva-
sion of Knosp grade III and IV,
15
 invasive GH – 
secreting pituitary adenoma may be unresectable due 
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Figure 2: Mean ± SEM serum concentration of GH (ng/ 
ml) in 03 female patients with NFPA and age – 
matched control subjects. The values with diffe-
rent superscripts (a, b) are different from each 
other (P < 0.05; ANOVA followed by Duncan‘s 
t-test). 
 
to the involvement with struc-
tures of the cavernous sinus; 
the GH level can‘t be norma-
lized, the surgical cure rate is 
low while the incidence of co-
mplications is high and the 
GH level must still be obser-
ved after the operation. 
 In general, adjuvant treat-
ment is necessary in patients 
with remnant tumors without 
remission. But, there is debate 
surrounding the starting point 
of adjuvant treatment. Al-
though the patient has not 
 
 
Table 3: Serum GH levels in female patients with Functioning Pituitary Ade-
nomas and in age – matched control subjects. 
 
 HUMAN GROWTH HORMONE SERUM SAMPLES 
   Pre-surgical Post-surgical 
ID Sex 
Age 
Years 
wt. of Pituitary 
adenoma (mg) 
Pre GH 
(ng/ml) 
Post GH 
(ng/ml) 
Control GH 
(ng/ml) 
P.A5 Female 23 49.8 33.6 15.3 0.1 
P.A13 Female 35 32.7 58.7   0.8 0.2 
P.A20 Female 50 18 24.2   0.9 0.2 
 
Table 4: Mean ± SEM serum GH levels of female 
patients with Functioning Pituitary Adeno-
mas and in normal subjects. 
 
Group 
Serum GH 
(ng/ml) 
Females 
Control Subjects (n = 03) 
Patients with pituitary adenoma (n = 03) 
  0.2 ± 0.6 
Pre-surgical 38.9 ± 10.3 
Post-surgical   5.7 ± 4.8* 
 
*Significantly different from pre-surgical and control value 
(P< 0.05; ANOVA followed by Duncan‘s t- test). 
achieved a hormonal remission state, careful observa-
tion could be an alternative option if there are no hor-
monal symptoms.
6, 26
 Since their introduction into 
clinical use more than a decade ago, the octreotide 
long – acting release (LAR) have been considered pri-
mary or secondary medical therapy for acromegaly. 
 In a recent study, it was found that there may be a 
role for pre-operative medical management if tumor 
shrinkage can be achieved prior to surgery. Surgical 
outcomes may also be improved by lowering preopera-
tive GH and IGF-I levels.
4,5
 For residual tumor within 
the cavernous sinus area after medical or surgical trea-
tment, gamma knife radiosurgery is a viable option. It 
is known from the present literature that although 
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gamma knife radiosurgery can be effective in con-
trolling the tumor volume of patients who are refrac-
tory to drug or surgical treatment, the biological cure 
rate is very low.
9,20,23,28
 
 Studies have claimed that GH values were norma-
lized in 62 – 83% of all acromegalic patients treated 
by fractionated radiotherapy over a 5 – 15 year per-
iod.
8,11
 
 Reported complications included optic neuropathy 
and pituitary insufficiency.
17
 Gamma knife radiosur-
gery is not only able to deliver a higher biological 
effective dose than fractionated radiotherapy, but it 
can do so without any of the usual associated compli-
cations.
9,17,23
 It can thus be strongly argued that gamma 
knife radiosurgery should be considered before fra-
ctionated radiotherapy as an adjuvant therapy. 
 The exact effect of cavernous sinus invasion on 
pituitary adenoma is unknown. However, the presence 
of a sensitive molecular marker for tumor invasiveness 
will allow a more focused and cost – effective follow-
up and long term management for these patients.
13
 
However, these markers can only provide limited pre-
dicting information. Recently, Isono et al.
12
 immuno-
histochemically examined the expression of leptin in 
pituitary adenomas and found that leptin expression 
correlated to the invasive potential of functioning ade-
nomas. The polysialylated neural cell adhesion mole-
cule was found strongly related to pituitary tumor in-
vasion.
27
 However, these factors have not been tested 
clinically, so further study is needed. TSS of GH – 
secreting pituitary adenoma continues to be a safe and 
effective method for dealing with a large number of 
patients with acromegaly. The goal of overall manage-
ment should be to provide the patient with the most 
effective means of long term control of this benign but 
potentially disabling disease. 
 The limitation of this study is being a prospective 
study in small number of patients. Therefore, a prospe-
ctive study in more patients will be necessary to fur-
ther evaluate the factors affecting the remission rate of 
acromegaly. It is hoped that with advances in pharma-
cotherapy, surgical treatment may become even more 
focused, more precise and more effective over time. 
 
CONCLUSION 
This article gives an insight on the treatment of acro-
megaly, especially on adenomas not invading the ca-
vernous sinus. On the basis of recent remission crite-
ria, our series demonstrate the good efficacy of TSS 
for acromegalic patients with microadenomas and non-
invasive macroadenomas. In patients with larger tum-
ors, cavernous sinus invasion or high preoperative GH 
levels, the remission rate is lower. Therefore, early 
detection of the tumor and a long – term endocrinolo-
gical and radiological follow-up may improve the re-
mission rate of acromegaly. 
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